9 Meters Biopharma (NASDAQ:NMTR) Posts Earnings Results, Hits Expectations

9 Meters Biopharma (NASDAQ:NMTR) released its quarterly earnings data on Saturday. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.06), Fidelity Earnings reports.

9 Meters Biopharma stock opened at $0.83 on Monday. The business’s fifty day moving average is $0.76. 9 Meters Biopharma has a one year low of $0.44 and a one year high of $1.11.

Several research firms recently weighed in on NMTR. William Blair reissued a “buy” rating on shares of 9 Meters Biopharma in a report on Thursday, September 24th. Zacks Investment Research cut 9 Meters Biopharma from a “buy” rating to a “hold” rating in a report on Wednesday, October 14th. Brookline Capital Management began coverage on 9 Meters Biopharma in a report on Tuesday, August 18th. They set a “buy” rating and a $5.00 price target for the company. HC Wainwright reissued a “buy” rating on shares of 9 Meters Biopharma in a report on Monday, September 21st. Finally, Maxim Group began coverage on 9 Meters Biopharma in a report on Friday, October 30th. They set a “buy” rating for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. 9 Meters Biopharma has a consensus rating of “Buy” and a consensus target price of $5.00.

In related news, CEO John Temperato acquired 70,000 shares of the stock in a transaction on Friday, August 21st. The shares were purchased at an average price of $0.69 per share, for a total transaction of $48,300.00. Following the purchase, the chief executive officer now directly owns 615,496 shares in the company, valued at $424,692.24. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Mark A. Sirgo purchased 50,000 shares of the firm’s stock in a transaction dated Thursday, September 10th. The stock was acquired at an average price of $0.60 per share, for a total transaction of $30,000.00. Following the purchase, the director now owns 461,784 shares in the company, valued at approximately $277,070.40. The disclosure for this purchase can be found here. 26.70% of the stock is owned by company insiders.

9 Meters Biopharma Company Profile

9 Meters Biopharma, Inc, a gastrointestinal platform company, focuses on patients with rare disorders and unmet needs. The company's pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease. It is developing NM-002, a long-acting injectable GLP-1 analogue for SBS; Larazotide, a Phase 3-stage therapeutic in development for celiac disease; and NM-003, a long-acting GLP-2 analogue, which is under orphan indication selection.

Further Reading: Pattern Day Trader – What is the PDT Rule?

Earnings History for 9 Meters Biopharma (NASDAQ:NMTR)

Receive News & Ratings for 9 Meters Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 9 Meters Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.